The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for HR-positive, HER2-low or HER2-ultralow metastatic breast cancer.

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer with disease progression after endocrine therapy.

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Dr. Won Jin Ho presented a talk as part of the Immunology Neighborhood Seminar on “Overcoming the tumor immune ...

for quantification and analysis of neutrophil cells expressing dsRed or EGFP in the CHT of zebrafish embryos. For macrophage analysis, a neutral red staining solution (final concentration of 2.5 mg/mL ...

Murine polymorphonuclear neutrophils (PMNs) were isolated from the bone marrow ... embedded in paraffin after fixation in 10% formalin for 24 h. Subsequently, HE staining was conducted on sections cut ...

Both for C57 wild-type BMCs treated in vitro and NZB/W BMCs from mice dosed orally, B-cell and pDC apoptosis was evaluated by annexin V staining using flow cytometry ... injury markers such as ...

A pioneering study has uncovered the complex and dual roles of neutrophils in cancer development, demonstrating their remarkable ability to both stimulate and suppress tumor growth. This research ...

This important study provides solid evidence to support the anti-tumor potential of citalopram, originally an anti-depression drug, in hepatocellular carcinoma (HCC). In addition to their previous ...

it didn’t occur to me that it might be a highly effective toilet bowl cleaner until I was faced with the persistent toilet stain situation. (I hate to even type those words.) I assumed it was ...